Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001225208-19-001889)

Filing Details

Accession Number:
0001225208-19-001889
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-06 17:30:15
Reporting Period:
2019-02-05
Accepted Time:
2019-02-06 17:30:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
310158 Merck & Co. Inc. MRK Pharmaceutical Preparations (2834) 221918501
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1181175 C Kenneth Frazier Merck &Amp; Co., Inc.
2000 Galloping Hill Road
Kenilworth NJ 07033		 Chairman, President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-02-05 231,566 $39.29 923,516 No 4 M Direct
Common Stock Disposition 2019-02-05 231,566 $78.08 691,950 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2019-02-05 231,566 $0.00 231,566 $39.29
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
463,132 2013-05-02 2022-05-01 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock - 401(K) Plan 4,010 Indirect By 401(k)
Footnotes
  1. The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.0000 to $78.3700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
  3. Holdings include shares acquired in dividend reinvestment transactions.
  4. Includes shares acquired and dividends earned through January 8, 2019, in the Merck U.S. Savings Plan, a 401(k) plan.
  5. The option became exercisable in equal installments on 5/2/2013, 5/2/2014 and 5/2/2015.